AB Science is stopping a late-stage clinical trial testing its oral drug masitinib as a treatment for progressive forms of multiple sclerosis (MS), saying this study and the therapy’s clinical development for MS are no longer a priority for the company. Instead, the developer will advance masitinib for…
Masitinib
Recommended Posts
- Doing everything we can to maintain cognitive reserve with MS
- FDA feedback supports new testing path for therapy in MS relapses
- Experts propose overhaul of longtime system describing MS types
- Hidden symptoms of migraine pain and MS make self-advocacy important
- Study finds many with MS don’t use available cooling options